Articles tagged with Cervical Cancer
HPV vaccination programs in Canada are currently limited, leaving men vulnerable to HPV-related diseases. The Canadian Medical Association Journal recommends expanding the programs to include males and negotiating with pharmaceutical companies to decrease costs.
A new HPV vaccine could significantly reduce cervical cancer incidence by 73% and healthcare costs if states coordinate policies to improve coverage. Increased funding can lead to improved vaccine coverage and public health.
A new study found a potential link between long-term oral nucleos(t)ide analogue treatment for hepatitis B and an increased risk of colorectal and cervical cancer. Regular screening is recommended to prevent these cancers in patients receiving such treatment. The study analyzed data from 45,299 patients with chronic HBV infection.
Researchers used SPECT-MRI fusion to assess sentinel lymph nodes in early-stage cervical cancer patients, finding that it could identify metastases with high accuracy. This non-invasive approach may reduce the need for surgical removal of lymph nodes and improve patient outcomes.
A study from Sahlgrenska Academy found that free gynecological pap test screenings did not increase participation among women in socioeconomically disadvantaged areas. Despite a low fee of SEK 11, the results showed only a slight difference in participation rates between those offered free screening and those who paid the usual fee.
A new study finds that most cancer screening guidelines do not adequately explain the risks and benefits of recommended actions, leading to unclear tradeoffs. Guidelines are often presented in a way that gives a false picture of the benefits and harms.
Adolescent girls living in high-poverty communities and majority Hispanic communities were more likely to have received the HPV vaccine. The poverty level of the community was also an important factor, with higher rates found in areas with lower socioeconomic status.
The University of Texas Health Science Center at Houston (UTHealth) has been awarded nearly $5.7 million in grants to support various cancer research projects and training initiatives. The grants will fund projects that increase breast and cervical cancer screening among Hispanics, as well as raise awareness about the human papillomavi...
A recent study involving one million patients found that follow-up times for abnormal screening exams were shorter for breast cancer than for colorectal and cervical cancers. The study characterized cancer screening practice variation across seven centers and noted the potential barriers to timely follow-up, including patient inconveni...
A new study recommends increasing investment in cancer control measures, including prevention, detection, diagnosis, treatment, and palliative care, in low- and middle-income countries. The authors suggest that most middle-income countries can achieve this coverage within a few years with cost-effective strategies.
Despite progress, cancer care in Latin America remains hindered by significant gaps in public expenditure on health and cancer care. The region still faces major challenges, including limited palliative care services, inadequate training in pain management, and underutilization of new technologies.
A multicomponent outreach program increased completion of the three-dose HPV vaccination series in adolescent girls, with mixed results by race/ethnicity. The study found that HPV vaccine-specific educational materials were effective for Hispanic parents, but not for African-American parents.
The updated guidelines, introduced in 2012, led to a 50% decrease in STI screenings and a significant drop in rates for gonorrhea and chlamydia. The study highlights the need for innovative ways to screen for STIs in young women.
Research reveals high rates of often preventable cancers among Indigenous populations in Australia, New Zealand, Canada, and the USA. These include lung, cervical cancer, with a significant impact from tobacco use. The study emphasizes the need for targeted prevention strategies to address cancer inequities.
The University of Hawai'i Cancer Center has been awarded a five-year $5.5 million grant to support research on cervical cancer, oral cancer, and other cancers affecting Pacific Islanders in the region. The partnership aims to reduce the disproportionate cancer burden in Pacific Island populations.
Researchers highlight key areas for cervical cancer prevention, including elearning programs and HPV infection studies. The Pan American Health Organization reports 36,000 deaths due to cervical cancer in the Americas, mostly in Latin America.
For patients with low pre-test probability of PE, applying PERC rule should guide diagnostic strategy. Imaging and testing can be reserved for those with high pre-test probability or contraindications to CT pulmonary angiography.
In a clinical trial, a genetically engineered vaccine successfully eradicated high-grade precancerous cervical lesions in 48.2% of women who received the vaccine, compared to 30% of those who received saline injections. The vaccine also cleared the virus from the cervixes of 56 women, reducing the risk of cancer recurrence.
Studies in the September Health Affairs issue reveal declining global mortality rates for heart disease, stroke, and certain cancers, but increasing trends in diabetes, liver cancer, respiratory disease, and lung cancer deaths, particularly among women and in low- and middle-income countries.
A study by Moffitt researchers found significant economic and health disparities in the LGBTQ community, including higher rates of poverty, lack of health services, and certain types of cancer. The study highlights the need for increased awareness and targeted interventions to address these disparities.
A study of 76 patients with cervical or endometrial cancer found that extended-field IMRT did not increase duodenal toxicity risk, even at high doses. The study confirms the safety of EF-IMRT for treating para-aortic lymph nodes.
A new analysis found a decline in high-grade cervical lesions among U.S. women aged 18-20 after HPV vaccination became available. However, this trend may be influenced by changes in cancer screening recommendations.
A recent study published in The Lancet Oncology suggests that a single dose of the HPV vaccine Cervarix can provide similar protection to three doses, offering hope for improving vaccination rates. This finding is particularly relevant for states like Kentucky with low completion rates.
A recent study has found that estrogen receptors are almost entirely absent in cervical cancer tumors, but still present in the tumor microenvironment. This finding highlights a critical communication between the microenvironment and tumor cells, allowing the tumor to thrive despite its inability to respond to estrogen.
A new study combining data from two large trials suggests that one dose of the bivalent HPV vaccine may be sufficient to protect against most cervical cancer cases, with high efficacy seen in women receiving one, two, or three doses. The findings have significant implications for global health, particularly in resource-poor settings wh...
A study in The Netherlands found that vaccinating girls against HPV also protects men from some cancers. The authors suggest that authorities prioritize vaccinating as many girls as possible, but consider including boys in preadolescent vaccination programs once costs and benefits align.
The 9-Valent human papillomavirus vaccine has the potential to protect against 80% of cervical cancers and approximately 19,000 other HPV-related cancers in the US. Researchers found that 70% of oropharyngeal cancer patient DNA samples harbored HPV, likely due to changes in sexual behaviors.
A USC study found that culturally relevant stories increased cervical cancer screenings among Latinas, while non-narrative approaches were less effective. The research used narrative videos with Mexican-American characters to reach this demographic and showed significant improvements in screening rates within six months.
The American College of Physicians (ACP) has released best practice advice for cervical cancer screening, supported by ACOG and ASCP. The guidance aims to reduce overuse of screening in average-risk women without symptoms.
The American College of Physicians (ACP) recommends starting cervical cancer screening at age 21 every three years with cytology tests, and using a combination of cytology and HPV testing every five years for women aged 30 and older. ACP advises stopping screening for women over 65 with negative test results within the past 10 years.
The ecancermedicalscience Special Issue celebrates the legacy of Dr. Mario Sideri, a pioneer in preventive gynecology. The nine articles cover topics such as screening techniques, HPV vaccine use, and E6/E7 mRNA testing for cervical intraepithelial disease.
A study of combined intracavitary and interstitial brachytherapy for cervical cancer treatment found that the technique delivers higher radiation doses to tumors without increasing treatment-related problems. The method successfully targets the tumor while avoiding other organs, leading to a better chance of cure.
A new study suggests that vaccinating 12-year-old boys against HPV can save $8 million to $28 million over their lifetimes due to reduced incidence of HPV-related oropharyngeal cancer. The study's findings have significant implications for public health policy in countries where HPV vaccination is not currently funded.
Women with inflammatory bowel disease (IBD) are at a higher risk of developing cervical dysplasia and cancer, according to a new study. Researchers found that patients with Crohn's disease had a significantly higher risk of cervical neoplasia, especially those diagnosed at a young age or treated with certain medications.
A Duke University study suggests that public health programs should allocate funds to encourage more boys to be vaccinated against human papillomavirus (HPV), which could ultimately protect more people. The study found that boosting HPV vaccination coverage in girls may become increasingly expensive as the pool of willing parents shrinks.
The HPV vaccine has been shown to be highly effective in preventing cervical cancers caused by nine high-risk HPV types. If populations are vaccinated, approximately 90% of all cervical cancers worldwide can be prevented. The vaccine was found to be safe with no significant health concerns.
A new HPV vaccine, Gardasil 9, has been developed to protect against nine types of the virus, significantly improving protection against cervical cancer compared to the current vaccine. The new vaccine offers up to 97% effectiveness in preventing high-grade cervical and vaginal disease caused by high-risk HPV types.
The HPV vaccine was highly effective against common cancer-causing human papillomaviruses beyond types 16 and 18. Young women vaccinated before sexual debut showed substantial protection against cervical abnormalities and precancerous cell transformations.
Douglas R. Lowy, MD, has been awarded the 2015 Harrington Prize for Innovation in Medicine for his key discoveries leading to the development of the human papillomavirus (HPV) vaccine. The vaccine has been shown to offer close to 100% protection against HPV-caused cancers.
Only about half of teenage girls receive the HPV vaccine at the recommended age of 11-12, leaving them unprotected against cervical cancer and genital warts. Researchers found that rates of HPV infection increase significantly among young people between 14-24, emphasizing the importance of early vaccination.
New research shows HPV infection screening alone is more accurate than Pap testing for detecting cervical cancer. The study suggests that HPV primary screening can be used as an alternative to current methods, with recommended 3-year intervals for testing.
A team of researchers from Central South University in China have demonstrated that photoacoustic imaging can distinguish cancerous from normal tissue and evaluate the stage of cervical cancer with high accuracy. This technique is non-invasive, faster, cheaper, and more effective than conventional methods like colposcopy.
Researchers have successfully treated cervical cancer patients with a combination of cidofovir and chemoradiation without increased toxic side effects. The treatment resulted in tumour shrinkage and complete response in 80% of patients, making it a promising new approach for HPV-related cancers.
A McGill University study found that men who had female partners with oral and/or genital HPV infections were more likely to have oral HPV themselves. The prevalence of oral HPV was higher among male smokers, non-monogamous individuals, and those with a partner having oral or genital HPV infection.
A human pilot study presented at the SIO meeting in Houston showed that AHCC can eliminate HPV infection in women. Five out of ten participants achieved a negative HPV test result after taking AHCC orally for up to five months, suggesting a potential breakthrough in cancer prevention and treatment.
A pilot clinical trial at UTHealth Medical School found that AHCC increased the number and activity of Natural Killer cells, helping fight off infections and tumor growth. Five women achieved negative HPV test results after six months of treatment, with confirmed eradication in three.
A recent study by Moffitt Cancer Center researchers found that men who consume more alcohol have a significantly higher risk of human papillomavirus (HPV) infection. The study analyzed over 1,300 men and discovered that those who drank the most alcohol had an increased risk of HPV independent of their number of sexual partners.
Adding cediranib to standard chemotherapy improves tumour shrinkage and adds a modest improvement in progression-free survival for patients with relapsed or metastatic cervical cancer. The study, published in Annals of Oncology, shows greater tumour shrinkage and increased median progression-free survival compared to chemotherapy alone.
A combination of chemotherapy drugs cisplatin and pemetrexed improved survival rates and response to advanced cervical cancer by 31% compared to standard alternative, while being less toxic to patients. Adding bevacizumab further increased patient survival, suggesting the cocktail may offer further benefits.
Researchers at Hera Therapeutics have developed a therapy that blocks replication of high-risk HPV types, including HPV-16 and HPV-18, which cause 70% of cervical cancer. The company is developing a topical approach to treat HPV infection, offering hope to millions of women infected with these high-risk strains.
Researchers found that personal biases and communication styles of providers played a significant role in decreasing HPV vaccination rates among teens. Providers who believed their patients were at low risk for sexual activity delayed vaccine administration, often without readdressing the decision.
The HPV vaccine has resulted in a dramatic drop in genital warts among young Australians, with a 90% decrease in girls aged 12-17 and a 73% decrease in women between 18-26. The vaccine also showed an indirect protective effect among young men, leading to a 38% drop in genital warts.
The study found that the HPV vaccine Cervarix provided 100% protection against HPV-16/18 infections over a period of 9.4 years, with high and sustained levels of IgG antibodies observed. The results suggest that the vaccine offered excellent persistence of protective immunity.
Researchers found a significant reduction in cervical cancer risk after removing squamocolumnar junction (SCJ) cells, which are implicated as the origins of cervical cancer. The study showed that removal of SCJ cells altered recurrence patterns and may prevent precancerous growths.
A recent study found that HPV testing alone provides similar reassurance against cervical cancer as cotesting and even more so than a negative Pap test. This suggests that primary HPV testing every 3 years could be an effective screening strategy.
Researchers found that bonuses did not improve breast and cervical cancer screening rates, but increased colorectal cancer screening by 4.7% per year. The study suggests alternative strategies like targeted outreach and public advertising campaigns may be more effective in improving cancer screening rates.
The American College of Physicians recommends against routine pelvic exams for asymptomatic, average-risk women due to low diagnostic accuracy and potential harms. The guideline suggests that pelvic exams are appropriate only for women with symptoms or certain risk factors.
Researchers recommend increasing cervical cancer screenings to reduce rates, regardless of test choice. Co-testing with Pap and HPV detects most pre-cancer, but improvement is small compared to repeat Pap testing every three years.
Increasing cervical cancer screening rates can help prevent invasive cancer. Experts recommend focusing on population coverage rather than choosing a specific test. Meanwhile, the release of Medicare data provides insights into healthcare spending and quality, but lacks meaningful context for evaluation.
Researchers have made significant strides in developing innovative immunotherapies that activate the body's immune response to fight cancer. The new treatments show high activity against advanced melanoma and demonstrate substantial decrease in melanoma recurrence risk.